Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain

Molecular and Cellular Biology

Volumn 18, Issue 7, 1998, Pages 3735-3743

  Frazier, Mark W ^a   He, Xiaoping ^a   Wang, Jinling ^a   Gu, Zhengming ^a   Cleveland, John L ^a,b   Zambetti, Gerard P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENHANCER REGION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE MAPPING; GENE MUTATION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; REPORTER GENE; TARGET CELL; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0031834336     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.7.3735     Document Type: Article

References (51)

1. Bentley, D., and M. Groudine. 1986. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 321:702-706.
2. Chen, Y., P.-L. Chen, and W.-H. Lee. 1994. Hot spot mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol. Cell. Biol. 14:6764-6772.
3. Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462.
4. Cleveland, J. L., M. Dean, N. Rosenberg, J. W.-Y. Wang, and U. R. Rapp. 1989. Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol. Cell. Biol. 9:5685-5696.
5. Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol. 66:6164-6170.
6. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A. K. Teresky, M. Moore, C. Finlay, and A. J. Levine. 1994. Gain-of-function mutations in p53. Nat. Genet. 4:42-46.
7. Duyao, M. P., D. J. Kessler, D. B. Spicer, C. Bartholomew, J. L. Cleveland, M. Siekevitz, and G. E. Sonenshein. 1992. Transaction of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NFκB. J. Biol Chem. 267:16288-16291.
8. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
9. Fontoura, B. M., E. A. Sorokina, E. David, and R. B. Carrol. 1992. p53 is covalently linked to 5.8S rRNA. Mol. Cell. Biol. 12:5145-5151.
10. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979-9983.
11. Gu, W., X.-L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819-823.
12. Gualberto, A., M. L. Hixon, T. S. Finco, N. D. Perkins, G. J. Nabel and A. S. Baldwin, Jr. 1995. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol. Cell. Biol. 15:3450-3459.
13. Harvey, D., and A. J. Levine. 1991. p53 alteration is a common event in the spontaneous immortalization of primary BALB/C murine fibroblasts. Genes Dev. 5:2375-2385.
14. Hinds, P. W., C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein and A. J. Levine. 1990. Mutant cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1:571-580.
15. Hsiao, M., J. Low, E. Dorn, D. Ku, P. Pattengale, J. Yeargin and M. Haas. 1994. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145:702-714.
16. Jeffrey, P. D., S. Gorina, and N. P. Pavletich. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498-1502.
17. Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
18. Kastan, M. B., Q. Zhan, W. S. el-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelaneiectasia. Cell 71:587-597.
19. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827.
20. Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for the transcriptional activation, binding to mdm-2 and the adenovirus 5E1B 55-kD protein. Genes Dev. 8:1235-1246.
21. Lin, J., A. K. Teresky, and A. J. Levine. 1995. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain-of-function phenotypes of human p53 mutants. Oncogene 10:2387-2390.
22. II31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92:5154-5158.
23. Ludes-Meyer, J., M. Subler, C. Shivakumar, R. Munoz, P. Jiang, J. Bigger, D. Brown, S. P. Deb, and S. Deb. 1996. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16:6009-6019.
24. Masuda, H., C. Miller, H. P. Koeffler, H. Battifora, and M. J. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad Sci. USA 84:7716-7719.
25. Meek, D. W., S. Simon, U. Kikkawa, and W. Eckhart. 1990. The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase H. EMBO J. 9:3253-3260.
26. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
27. 1 checkpoint after DNA damage. Mol. Cell. Biol. 16:1126-1137.
28. Mosner, J., T. Mummenbrauer, C. Bauer, G. Sczakiel, F. Grosse, and W. Deppert. 1995. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:4442-4449.
29. Nepveu, A., and K. B. Marcu. 1986. Intragenic pausing and anti-sense transcription within the murine c-myc locus. EMBO J. 5:2859-2865.
30. Oberosler, P., P. Hloch, U. Ramsperger, and H. Stahl. 1993. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 12: 2389-2396.
31. Pellagata, N. S., J.-F. Cajot, and E. J. Standbridge. 1995. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene 11:337-349.
32. Santhanam, U., A. Rat, and P. B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 88:7605-7609.
33. Selivanova, G., V. Iotsova, E. Kiseleva, M. Strom, G. Bakalkin, R. C. Grafstrom, and K. G. Wiman. 1996. The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res. 24:3560-3567.
34. Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89:12028-12032.
35. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581-5592.
36. Shaulian, E., A. Zauberman, J. Milner, E. A. Davies, and M. Oren. 1993. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J. 12:2789-2797.
37. Shaulsky, G., N. Goldfinger, A. Ben-Ze'ev, and V. Rotter. 1990. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:6565-6577.
38. Shaulsky, G., N. Goldfinger, and V. Rotter. 1991. Alterations in tumor development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res. 51:5232-5237.
39. Slingerland, J., J. Jenkins, and S. Benchimol. 1993. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J. 12:1029-1037.
40. Spencer, C. A., and M. Groudine. 1991. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56:1-48.
41. Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757-4762.
42. Sun, Y., K. Nakamura, E. Wendel, and N. Colburn. 1993. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma. Proc. Natl. Acad. Sci USA 90:2827-2831.
43. II60. Science 267:100-103.
44. Wolf, D., N. Harris, and V. Rotter. 1984. Reconstitution of p53 expression in a nonproducer Ab-MuLV transformed cell line by transfection of a functional p53 gene. Cell 38:119-126.
45. Wright, S., and J. M. Bishop. 1989. DNA sequences that mediate attenuation of transcription from the mouse protooncogene myc. Proc. Natl. Acad. Sci. USA 86:505-509.
46. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
47. Wu, L., J. H. Bayle, B. Elenbaas, N. P. Pavletich, and A. J. Levine. 1995. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15:497-504.
48. Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J. L. Regier, S. J. Triezenberg, D. Reinberg, O. Flores, C. J. Ingles, and J. Greenblatt. 1994. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol. 14:7013-7024.
49. Zambetti, G. P., D. Olson, M. A. Labow, and A. J. Levine. 1992. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc. Natl. Acad. Sci. USA 89:3952-3956.
50. Zambetti, G. P., J. Bargonetti, K. Walker, C. Prives, and A. J. Levine. 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6:1143-1152.
51. Zambetti, G. P., and A. J. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 8:855-865.